Is Thermo Fisher Scientific (NYSE:TMO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Thermo Fisher Scientific at current levels.
The picks-and-shovels giant of biopharma is on sale because everyone hates biopharma. That's the whole trade.
Where TMO is headed
Thermo Fisher is the toll booth on every drug, every clinical trial, every academic lab bench, and every diagnostic test in the Western world. At $442, it trades like a cyclical industrial having a bad year. It is not. It is a 40% gross margin compounder with $5.5B in free cash flow, growing high single digits through the worst biopharma funding winter since 2008. The market is currently pricing the worst chapter (China weakness, NIH budget anxiety, post-COVID normalisation in PPD clinical trials) and ignoring what comes next.
Read the full Compass Direction on TMO
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios.
See the full TMO analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Thermo Fisher Scientific (NYSE:TMO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Thermo Fisher Scientific at current levels. The picks-and-shovels giant of biopharma is on sale because everyone hates biopharma. That's the whole trade.
What is TMO's Compass Score?
Thermo Fisher Scientific scores 41/100 on Alexandria's Compass, placing it in the "Neutral" tier. Scores blend eight factors and update weekly.
What is the price target for TMO?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the TMO page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.